KELLY STRATEGIC CRISPR & GENE EDITING TECHNOLOGY ETF - USD |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.38 USD | -1.60% |
|
-2.45% | -25.75% |
Investment objective
XDNA seeks to track the total return performance, before
fees and expenses, of the Strategic CRISPR & Gene Editing
Technology Index, which measures the performance of
companies that specialize in CRISPR & DNA modification
systems, and technologies, for variety of applications
including basic biological research, development of
biotechnological products, and treatment of diseases as well
as next-generation sequencing that may be used at various
stages of a genome editing workflow.
| Name |
Price
|
Change
|
5d. change
|
1st Jan change
|
Weight
| |
|---|---|---|---|---|---|---|
| 573.6 USD | +0.33% | +5.29% | +8.07% | 11.69% | ||
| 20.76 USD | +3.70% | -3.76% | -31.91% | 11.15% | ||
| 53.91 USD | +0.34% | -2.07% | -13.88% | 8.55% | ||
| 21.38 USD | -1.02% | -10.54% | -21.45% | 8.03% | ||
| 3.71 USD | -1.33% | -3.64% | -35.25% | 6.97% | ||
| 2.13 USD | +3.90% | +5.45% | -36.61% | 4.87% | ||
| 5.32 USD | +1.92% | -3.10% | -47.48% | 4.83% | ||
| 159.6 USD | -4.58% | -4.08% | +3.00% | 4.81% | ||
| 4.425 USD | +2.91% | -1.88% | -50.06% | 4.71% | ||
| 6.16 USD | -0.96% | -7.23% | -55.81% | 4.13% | ||
More news
In partnership with
Description
| US48817R7061 | |
|---|---|
| Total Expense Ratio | 0.78% |
| Asset Class | |
| Sector | |
| Size | |
| Currency | |
| Provider | |
| Underlying | Strategic CRISPR & Gene Editing Technology Index NR - USD |
Features and characteristics
| Jurisdiction | |
| Replication Method | |
| Replication Model | |
| Date of creation |
2022-01-11
|
| Dividend Policy | |
| Geographical Focus |
AuM evolution ( 2023-10-30 )
| AuM (EUR) | 2 M€ |
|---|---|
| AuM 1M | 2 M€ |
| AuM 3 months | 2 M€ |
| AuM 6 months | 2 M€ |
| AuM 12 months | 5 M€ |
- Stock Market
- ETF
- XDNA ETF
